Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- EPS Goes Public, First Listed CRO in Japan
June 4, 2001
- COPRORATE ROUNDUP NEWS IN BRIEF -4-
June 4, 2001
- BUSINESS NEWS IN BRIEF
June 4, 2001
- COPRORATE ROUNDUP NEWS IN BRIEF -5-
June 4, 2001
- JACDS Makes Proposals for Nursing Care Business at Drugstores
June 4, 2001
- Wholesalers' Profits Plummet due to Tough Negotiation on Price
June 4, 2001
- Fujisawa Licenses Osteoporosis Drug from Servier
June 4, 2001
- COPRORATE ROUNDUP NEWS IN BRIEF -1-
June 4, 2001
- Shionogi to Launch MS Contin in Small Packages
June 4, 2001
- COPRORATE ROUNDUP NEWS IN BRIEF -2-
June 4, 2001
- Takeda to Increase OTC Sales to \100 Bil. in 2005
June 4, 2001
- COPRORATE ROUNDUP NEWS IN BRIEF -3-
June 4, 2001
- Efco, Kyuyukai to Merge in Fall
June 4, 2001
- Continuing Growth by Focusing on Specialty Pharmaceuticals: Mr Pyott of Allergan
June 4, 2001
- Takiya Shoji, Drux to Merge in August
June 4, 2001
- Listing of 14 Active Ingredients Including Radicut, Zyprexa Approved
June 4, 2001
- Taisho Terminates Business with Daikoku Group
June 4, 2001
- Peak-time Sales of Radicut, Zyprexa Expected to Top \10 Bil.
June 4, 2001
- NEW PRODUCTS NEWS IN BRIEF
June 4, 2001
- Chuikyo to Review NHI Pricing Rule
June 4, 2001
ページ
The launch of Elevidys has opened the door to gene therapy for DMD, but research into new treatments is already…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…